BIOMAT Database Logo BIOMAT Database Logo

Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam. 2017

Marc Xipell, and Marta Bodro, and Francesc Marco, and José A Martínez, and Alex Soriano
Infectious Diseases Department, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.

Ceftolozane/tazobactam is a novel fifth-generation cephalosporin β-lactamase combination with activity against extended-spectrum β-lactamases-producing enterobacteriaceae, and multidrug resistant Pseudomonas aeruginosa. However, clinical experience in real cases caused by these microorganisms is scarce. In this study, we describe three patients with severe infections caused by multidrug resistant and extensively drug-resistant (XDR) P. aeruginosa that were successfully treated with ceftolozane/tazobactam.

UI MeSH Term Description Entries
D008297 Male Males
D010397 Penicillanic Acid A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed) Acid, Penicillanic
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078142 Tazobactam A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria. Tazobactam Sodium,YTR 830,YTR 830H,YTR-830,YTR830
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Marc Xipell, and Marta Bodro, and Francesc Marco, and José A Martínez, and Alex Soriano
Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.
August 2018, Infection,
Marc Xipell, and Marta Bodro, and Francesc Marco, and José A Martínez, and Alex Soriano
Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam.
April 2017, The Journal of antimicrobial chemotherapy,
Marc Xipell, and Marta Bodro, and Francesc Marco, and José A Martínez, and Alex Soriano
Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.
September 2017, The Journal of antimicrobial chemotherapy,
Marc Xipell, and Marta Bodro, and Francesc Marco, and José A Martínez, and Alex Soriano
Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study.
July 2022, European journal of drug metabolism and pharmacokinetics,
Marc Xipell, and Marta Bodro, and Francesc Marco, and José A Martínez, and Alex Soriano
Use of Ceftolozane-Tazobactam in Patient with Severe Medium Chronic Purulent Otitis by XDR Pseudomonas aeruginosa.
January 2019, Case reports in infectious diseases,
Marc Xipell, and Marta Bodro, and Francesc Marco, and José A Martínez, and Alex Soriano
Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
February 2017, Infection,
Marc Xipell, and Marta Bodro, and Francesc Marco, and José A Martínez, and Alex Soriano
In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece.
August 2020, The Journal of antimicrobial chemotherapy,
Marc Xipell, and Marta Bodro, and Francesc Marco, and José A Martínez, and Alex Soriano
Ceftolozane/Tazobactam Treatment of Multidrug-resistant Pseudomonas aeruginosa Infections in Children.
May 2020, The Pediatric infectious disease journal,
Marc Xipell, and Marta Bodro, and Francesc Marco, and José A Martínez, and Alex Soriano
Successful treatment of multidrug-resistant Pseudomonas aeruginosa pubic symphysis osteomyelitis with ceftolozane/tazobactam.
March 2017, BMJ case reports,
Marc Xipell, and Marta Bodro, and Francesc Marco, and José A Martínez, and Alex Soriano
Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia.
May 2018, Expert review of anti-infective therapy,
Copied contents to your clipboard!